Search research articles
Contact Us
Filters
Showing results (211-220 of 346) with videos related to
Page
of 35
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
August 25, 2024
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia
Jason Yeh, Oren Pasvolsky, Rima M Saliba, et al.
Cancer
|
May 29, 2024
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation
Jayastu Senapati, Hagop M Kantarjian, Alexandre Bazinet, et al.
Cancer
|
April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Elias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
American Journal of Hematology
|
July 31, 2016
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy
Nicholas J Short, Christopher B Benton, Hsiang-Chun Chen, et al.
American Journal of Hematology
|
September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes
Daniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
JCO Precision Oncology
|
May 17, 2023
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class Rearrangements
Jayastu Senapati, Elias Jabbour, Marina Konopleva, et al.
Blood Advances
|
December 19, 2023
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Alex Bataller, Alexandre Bazinet, Courtney D DiNardo, et al.
American Journal of Hematology
|
January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
Elias Jabbour, Paolo Strati, Monica Cabrero, et al.
Cancers
|
November 27, 2024
Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience
David McCall, Shaikha Alqahtani, Moriah Budak, et al.
JNCI Cancer Spectrum
|
June 27, 2025
Risk of early death after acute leukemia diagnosis among adolescents and young adults
Amy M Berkman, Clark R Andersen, Vidya Puthenpura, et al.
Page
of 35
Search research articles
Search
Showing results (211-220 of 346) with videos related to
Sort By:
Page
of 35
Clinical Lymphoma, Myeloma & Leukemia
|
August 25, 2024
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia
Jason Yeh, Oren Pasvolsky, Rima M Saliba, et al.
Cancer
|
May 29, 2024
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation
Jayastu Senapati, Hagop M Kantarjian, Alexandre Bazinet, et al.
Cancer
|
April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Elias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
American Journal of Hematology
|
July 31, 2016
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy
Nicholas J Short, Christopher B Benton, Hsiang-Chun Chen, et al.
American Journal of Hematology
|
September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes
Daniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
JCO Precision Oncology
|
May 17, 2023
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class Rearrangements
Jayastu Senapati, Elias Jabbour, Marina Konopleva, et al.
Blood Advances
|
December 19, 2023
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Alex Bataller, Alexandre Bazinet, Courtney D DiNardo, et al.
American Journal of Hematology
|
January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
Elias Jabbour, Paolo Strati, Monica Cabrero, et al.
Cancers
|
November 27, 2024
Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience
David McCall, Shaikha Alqahtani, Moriah Budak, et al.
JNCI Cancer Spectrum
|
June 27, 2025
Risk of early death after acute leukemia diagnosis among adolescents and young adults
Amy M Berkman, Clark R Andersen, Vidya Puthenpura, et al.
Page
of 35